Publication date: Jun 21, 2025
Pacific region-specific data on the clinical course of COVID-19 are limited. We aimed to describe clinical features and outcomes from Aotearoa New Zealand patients, focusing on Māori and Pacific peoples. We conducted a retrospective cohort study among adults (≥16 years) hospitalised due to COVID-19 at 11 hospitals from January to May 2022. We included all Māori and Pacific patients and every second non-Māori, non-Pacific (NMNP) patient using data from chart review and national datasets. Of 2319 patients, 582 (25%) were Māori, 914 (39%) Pacific peoples and 862 NMNP (median age 52, 57 and 63 years respectively). Vaccination coverage (≥2 doses) was 73. 4% (n = 437) for Māori, 76. 7% (n = 701) for Pacific peoples (n = 701) and 84. 8% (n = 731) for NMNP. Among 832 (35. 9%) with complications, Māori had a greater risk than NMNP of acute kidney injury (risk ratio (RR) 1. 87, P
| Concepts | Keywords |
|---|---|
| Hospitals | COVID‐19 |
| Kidney | indigenous health |
| Zealand | New Zealand |
| Pacific |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | complications |
| disease | MESH | COVID-19 |
| disease | MESH | clinical course |
| disease | MESH | acute kidney injury |